A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

The key inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: * Has a BMI ≥18.5 and ≤35 kg/m2 * Diagnosis of chronic (\>6 months) stable Hepatic Impairment (HI) with features of cirrhosis due to any etiology (Moderate HI arm only) * Has a score on the Child-Pugh scale ranging from 7 to 9 (Moderate HI arm only) * In good health (except for Moderate HI) Exclusion Criteria: * Anticipated survival of \<3 months (Moderate HI arm only) * Received antiviral and/or immune modulating therapy (Moderate HI only) for Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) within 90 days prior to study start * History of clinically significant abnormalities or diseases (Healthy matched arm only). * History of cancer * Major surgery and/or donated or lost 1 unit of blood * Taking medications to treat chronic medical conditions and has not been on a stable regimen for at least 1 month (Moderate HI arm only) and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 8 hours after administration of the study drug.